natgillin/translations-raw huggingface dataset:
Puregon 225 IU/0.5 mL solution for injection follitropin beta
Puregon 225 i.e./0,5 ml raztopina za injiciranje folitropin beta
Puregon 300 IU/0.36 mL injection follitropin beta
Puregon 300 i.e./0,36 ml injekcija folitropin beta
Puregon 50 IU/0.5 mL injection follitropin beta
Puregon 50 i.e./0,5 ml injekcija folitropin beta
Puregon 50 IU/0.5 mL solution for injection follitropin beta
Puregon 50 i.e./0,5 ml raztopina za injiciranje folitropin beta
Puregon 600 IU/0.72 mL injection follitropin beta
Puregon 600 i.e./0,72 ml injekcija folitropin beta
Puregon 75 IU/0.5 mL injection follitropin beta
Puregon 75 i.e./0,5 ml injekcija folitropin beta
Puregon 75 IU/0.5 mL solution for injection follitropin beta
Puregon 75 i.e./0,5 ml raztopina za injiciranje folitropin beta
Puregon 900 IU/1.08 mL injection follitropin beta
Puregon 900 i.e./1,08 ml injekcija folitropin beta
Puregon is given as a ‘subcutaneous’ injection (under the skin) or into a muscle.
Zdravilo Fertavid se daje s subkutano injekcijo (pod kožo) ali v mišico.
Puregon may contain traces of streptomycin and/or neomycin.
Zdravilo Puregon lahko vsebuje sledi streptomicina in/ali neomicina.
Puregon should be given at a dosage of 450 IU/week, preferably divided in 3 dosages of 150 IU, concomitantly with hCG.
Moškim dajte 450 i.e. zdravila Puregon na teden, najbolje v 3 odmerkih po 150 i.e., skupaj s hCG.
Puregon solution for injection in cartridges 150 IU/0.18 mL, 300 IU/0.36 mL, 600 IU/0.72 mL, 900 IU/1.08 mL:
Puregon raztopina za injiciranje v vložkih 150 i.e./0,18 ml, 300 i.e./0,36 ml, 600 i.e./0,72 ml, 900 i.e./1,08 ml:
Puregon solution for injection in vials 50 IU/0.5 mL, 75 IU/0.5 mL, 100 IU/0.5 mL, 150 IU/0.5 mL, 200 IU/0.5 mL, 225 IU/0.5 mL:
Puregon raztopina za injiciranje v vialah 50 i.e./0,5 ml, 75 i.e./0,5 ml, 100 i.e./0,5 ml, 150 i.e./0,5 ml, 200 i.e./0,5 ml, 225 i.e./0,5 ml:
Puregon’s use in women undergoing fertility treatment has been studied in 981 patients.
Uporaba zdravila Puregon pri ženskah, ki se zdravijo zaradi neplodnosti, je bila raziskana pri 981 bolnicah.
PUREN Pharma GmbH & Co. KG Tel.: +49-89-558-9090
KG Telefon: +49 (0)89 558909 0
Purevax FeLV contains genes from the FeLV sub-group A called env and gag which have been inserted into another vector (carrier) virus called canarypox using ‘recombinant DNA technology’.
Zdravilo Purevax FeLV vsebuje gene virusa FeLV podskupine A, imenovane env in gag, ki so jih s pomočjo „tehnologije rekombinantne DNA“ vstavili v drug vektorski (prenašalni) virus, imenovan poxvirus kanarčkov.
Purevax FeLV Suspension for injection
Purevax FeLV Suspenzija za injiciranje
Purevax FeLV Suspension for injection
Purevax FeLV Suspenzija za injiciranje.
Purevax RC contains small amounts of weakened or killed viruses that cause the diseases listed above.
Zdravilo Purevax RC vsebuje majhne količine oslabljenih oblik ali uničenih virusov, ki povzročajo zgoraj navedeni bolezni.
Purevax RC is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Zdravilo Purevax RC je v obliki liofilizata (pelete, posušene v zamrznjenem stanju) in vehikla, iz katerih se pripravi suspenzija za injiciranje.
Purevax RC is a vaccine containing the following active substances: attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains).
Zdravilo Purevax RC je cepivo, ki vsebuje naslednje zdravilne učinkovine: atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), inaktivirane (uničene) antigene kalicivirusa mačk (seva FCV 431 in G1).
Purevax RC is used to vaccinate cats from the age of 8 weeks against the following diseases:
Zdravilo Purevax RC se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjima boleznima:
Purevax RC lyophilisate and solvent for suspension for injection
Purevax RC liofilizat in vehikel za suspenzijo za injiciranje
Purevax RC lyophilisate and solvent for suspension for injection.
Purevax RC Liofilizat in vehikel za suspenzijo za injiciranje
Purevax RC should not be used in pregnant cats.
Zdravilo Purevax RC se ne sme uporabljati za breje mačke.
Purevax RC solvent
Purevax RC vehikel
Purevax RCCh is a vaccine containing the following active substances: attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), attenuated Chlamydophila felis (905 strain).
Zdravilo Purevax RCCh je cepivo, ki vsebuje naslednje zdravilne učinkovine: atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), inaktivirane (uničene) antigene kalicivirusa mačk (seva FCV 431 in G1), atenuirano bakterijo Chlamydophila felis (sev 905).
Purevax RCCh lyophilisate and solvent for suspension for injection
Purevax RCCh liofilizat in vehikel za suspenzijo za injiciranje
Purevax RCCh lyophilisate for injection
Purevax RCCh liofilizat za injiciranje.
Purevax RCCh solvent
Purevax RCCh vehikel
Purevax RCP contains small amounts of weakened or killed viruses that cause the diseases listed above.
Zdravilo Purevax RCP vsebuje majhne količine oslabljenih oblik ali uničenih virusov, ki povzročajo zgoraj navedene bolezni.
Purevax RCP FeLV contains small amounts of weakened or killed viruses that cause the diseases listed above, as well as two genes from the FeLV called env and gag, which have been inserted into another vector (carrier) virus called canarypox using ‘recombinant DNA technology’.
Zdravilo Purevax RCP FeLV vsebuje majhne količine oslabljenih ali uničenih virusov, ki povzročajo zgoraj navedene bolezni, ter dva gena virusa FeLV, imenovana env in gag, ki so ju s „tehnologijo rekombinantne DNA“ vstavili v drug virusni (prenašalni) vektor, imenovan poxvirus kanarčkov.
Purevax RCP FeLV is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Zdravilo Purevax RCP FeLV je liofilizat (peleta, posušena v zmrznjenem stanju) in vehikel za pripravo suspenzije za injiciranje.
Purevax RCP FeLV is a vaccine containing the following active substances: attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), attenuated feline panleucopenia virus (PLI IV), feline leukaemia virus (FeLV) recombinant canarypox virus (vCP97).
Zdravilo Purevax RCP FeLV je cepivo, ki vsebuje naslednje zdravilne učinkovine: atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), inaktivirane (uničene) antigene kalicivirusa (sev FCV 431 in G1), atenuirani virus panleukopenije mačk (PLI IV), rekombinantni poxvirus kanarčkov (vCP97), ki vsebuje antigen virusa mačje levkemije (FeLV).
Purevax RCP FeLV is used to vaccinate cats from the age of 8 weeks against the following diseases:
Zdravilo Purevax RCP FeLV se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjim boleznim:
Purevax RCP FeLV lyophilisate and solvent for suspension for injection
Purevax RCP FeLV liofilizat in vehikel za suspenzijo za injiciranje
Purevax RCP FeLV solvent
Purevax RCP FeLV vehikel
Purevax RCP is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Zdravilo Purevax RCP je v obliki liofilizata (pelete, posušene v zamrznjenem stanju) in vehikla, iz katerih se pripravi suspenzija za injiciranje.
Purevax RCP is a vaccine containing the following active substances: attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), attenuated feline panleucopenia virus (PLI IV).
Zdravilo Purevax RCP je cepivo, ki vsebuje naslednje zdravilne učinkovine: atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), inaktivirane (uničene) antigene kalicivirusa mačk (seva FCV 431 in G1), atenuirani virus panlevkopenije mačk (PLI IV).
Purevax RCP is used to vaccinate cats from the age of 8 weeks against the following diseases:
Zdravilo Purevax RCP se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjim boleznim:
Purevax RCP lyophilisate and solvent for suspension for injection
Purevax RCP liofilizat in vehikel za suspenzijo za injiciranje
Purevax RCP should not be used in pregnant cats.
Zdravilo Purevax RCP se ne sme uporabljati za breje mačke.
Purevax RCP solvent
Purevax RCP vehikel
Purevax RCPCh contains small amounts of weakened or killed viruses and bacteria that cause the diseases listed above.
Zdravilo Purevax RCPCh vsebuje majhne količine oslabljenih ali uničenih virusov in bakterij, ki povzročajo zgoraj navedene bolezni.
Purevax RCPCh FeLV is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Zdravilo Purevax RCPCh FeLV je liofilizat (peleta, posušena v zmrznjenem stanju) in vehikel za pripravo suspenzije za injiciranje.
Purevax RCPCh FeLV is a vaccine containing the following active substances: attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), attenuated Chlamydophila felis (905 strain), attenuated feline panleucopenia virus (PLI IV), feline leukaemia virus (FeLV) recombinant canarypox virus (vCP97).
Zdravilo Purevax RCPCh FeLV je cepivo, ki vsebuje naslednje zdravilne učinkovine: atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), inaktivirane (uničene) antigene kalicivirusa (sev FCV 431 in G1), atenuirano bakterijo Chlamydophila felis (sev 905), atenuirani virus panleukopenije mačk (PLI IV), rekombinantni poxvirus kanarčkov (vCP97), ki vsebuje antigen virusa mačje levkemije (FeLV).
Purevax RCPCh FeLV is used to vaccinate cats from the age of 8 weeks against the following diseases:
Zdravilo Purevax RCPCh FeLV se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjim boleznim:
Purevax RCPCh FeLV lyophilisate and solvent for suspension for injection.
Purevax RCPCh FeLV liofilizat in vehikel za suspenzijo za injiciranje
Purevax RCPCh FeLV solvent
Purevax RCPCh FeLV vehikel
Purevax RCPCh is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Zdravilo Purevax RCPCh je liofilizat (peleta, posušena v zmrznjenem stanju) in vehikel za pripravo suspenzije za injiciranje.
Purevax RCPCh is a vaccine containing the following active substances: attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), attenuated Chlamydophila felis (905 strain), attenuated feline panleucopenia virus (PLI IV).
Zdravilo Purevax RCPCh je cepivo, ki vsebuje naslednje zdravilne učinkovine: atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), inaktivirane (uničene) antigene kalicivirusa (sev FCV 431 in G1), atenuirano bakterijo Chlamydophila felis (sev 905), atenuirani virus panleukopenije mačk (PLI IV).
Purevax RCPCh is used to vaccinate cats from the age of 8 weeks against the following diseases:
Zdravilo Purevax RCPCh se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjim boleznim:
Purevax RCPCh lyophilisate and solvent for suspension for injection
Purevax RCPCh liofilizat in vehikel za suspenzijo za injiciranje
Purevax RCPCh solvent
Purevax RCPCh vehikel
Purified diphtheria toxoid ....................................................... equal to or greater than 20 IU* (30 Lf)
Prečiščen davični toksoid ....................................................... ne manj kot 20 i.e.* (30 Lf)
Purified diphtheria toxoid ....................................................................... 20 IU
Prečiščen davični toksoid .......................................................................20 i.e.
Purified diphtheria toxoid ....................................................................... 20 IU
Prečiščen davični toksoid ......................................................................20 i.e.
Purified diphtheria toxoid ....................................................................... 20 IU
Prečiščen toksoid davice.........................................................................20 i.e
Purified diphtheria toxoid ....................................................................... 20 IU
Prečiščen toksoid davice.........................................................................20 i.e.
Purified extract of Quillaja saponaria (QA-21) 60 µg
Prečiščeni ekstrakt Quillaja saponaria (QA-21): 60 µg
Purified extract of Quillaja saponaria 10 µg
Prečiščen izvleček Quillaja saponaria 10 µg
Purified extract of Quillaja saponaria: 10 µg
Prečiščen izvleček čilskega milovca (Quillaja saponaria):
Purified galsulfase, a recombinant form of human N-acetylgalactosamine 4-sulfatase, is a glycoprotein with a molecular weight of approximately 56 kD.
Prečiščena galsulfaza, rekombinantna oblika humane N-acetilgalaktozamin-4-sulfataze, je glikoprotein z molekulsko maso približno 56 kD.
Purified laronidase is a glycoprotein with a molecular weight of approximately 83 kDa.
Očiščena laronidaza je glikoprotein z molekularno maso približno 83 kDa.
Purified p45 FeLV-envelope antigen, minimum quantity 102 μg
Minimalna količina prečiščenega antigena ovojnice p 45FeLV 102 µg
Purified pertussis toxoid .........................................................................
Prečiščen toksoid bordetele pertusis .......................................................
Purified pertussis toxoid .........................................................................25 µg
25 µg Prečiščen filamentozni hemaglutinin bordetele pertusis.........................
Purified saponin 250 micrograms
prečiščeni saponin 250 mikrogramov
Purified Saponin 375 micrograms
Prečiščeni saponin 375 mikrogramov
Purified Saponin 375 µg
Prečiščeni saponin 375 µg
Purified subunit vaccine for the active immunisation of pregnant bitches to induce passive immunity in puppies against herpesvirus-induced fatal neonatal disease.
Prečiščena podskupina cepiva za aktivno imunizacijo brejih psic in pasivno zaščito mladičev proti smrtnim neonatalnim boleznimm, ki jih povzroča herpes virus.
Purified tetanus toxoid............................................................ equal to or greater than 40 IU* (10 Lf)
Prečiščen tetanusni toksoid..................................................... ne manj kot 40 i.e.* (10 Lf) Prečiščen toksoid bordetele pertusis .......................................
Purified tetanus toxoid............................................................................ 40 IU
Prečiščen tetanusni toksoid..................................................................... 40 i.e.
Purified tetanus toxoid............................................................................ 40 IU
Prečiščen toksoid tetanusa ......................................................................40 i.e.
Purified tetanus toxoid............................................................................ 40 IU
Prečiščentetanusni toksoid......................................................................40 i.e.
Purified water Hydroxyethylcellulose Glycerol
prečiščena voda hidroksietilceluloza glicerol
Purified, inactivated foot-and-mouth disease virus strain antigens, at least 6 cattle PD50*per strain.
Prečiščeni, inaktivirani antigeni virusa slinavke in parkljevke, vsaj 6 ZO50 za govedo* na sev
purple
vijoličast
purple
vijoličen
Purple 20 microgram pen activation
Aktivacija škrlatnega peresnika 20 mikrogramov
Purple 20 microgram pen Use
Uporaba škrlatnega peresnika 20 mikrogramov
purple bruising and swelling of your penis difficulty urinating or blood in the urine
vijolično modrico in oteklino penisa težave z uriniranjem ali kri v urinu
purple coloured rash pain
izpuščaj vijolične barve bolečina
purple discoloration of the skin, solid bumps on the skin, rash, yellow bumps on the skin
vijoličasto obarvanje kože, trdne izbokline na koži, izpuščaj, rumene izbokline na koži,
Purple dual chamber pipette: The primary packaging is composed of two heat-formed polyolefin chambers with a central polyolefin-coated aluminium partition.
Vijoličaste merilne kapalke z dvema razdelkoma: primarno pakiranje sestavljata dva toplotno oblikovana razdelka iz poliolefinov s predelno steno iz s poliolefini prevlečenega aluminija.
Purple needle safety shield
vijolični varnostni ščit igle
Purple or red brown spots visible through the skin (thrombocytopenic purpura)
rdeče ali rdečerjave lise, ki se vidijo skozi kožo (trombocitopenična purpura)
Purple or red brown spots visible through the skin (thrombocytopenic purpura)
rdeče ali rdečerjave lise, ki se vidijo skozi kožo (trombocitopenična purpura),
Purple or red brown spots visible through the skin (thrombocytopenic purpura)
rdeče ali rdečerjave lise, ki se vidijo skozi kožo (trombocitopenična purpura);
Purple or reddish-purple bumps on the skin (lichen planus), serious skin rashes (erythema multiforme)
škrlatne ali rdeče-škrlatne izbokline na koži (lichen planus), močan kožni izpuščaj (multiformni eritem), koprivnica;
purple or reddish-purple bumps on the skin (lichen planus), serious skin rashes (erythema multiforme) reduction in blood platelets, which increases risk of bleeding or bruising (thrombocytopenia), purple or red brown spots visible through the skin (thrombocytopenic purpura)
vijoličaste ali rdeče vijoličaste bunčice na koži (lichen planus), resna oblika izpuščaja na koži (multiformni eritem), zmanjšanje števila krvnih ploščic, ki poveča tveganje za krvavitve ali podplutbe (trombocitopenija), vijoličaste ali rdečerjave pike, vidne skozi kožo (trombocitopenična purpura).
Purple or reddish-purple bumps on the skin (lichen planus), serious skin rashes (erythema multiforme), hives
škrlatne ali rdeče-škrlatne izbokline na koži (lihen planus), močan kožni izpuščaj (multiformni eritem), koprivnica,
purple skin patches
vijolične kožne lise
purple skin patches
vijolične lise na koži
purple skin patches kidney disorders
vijolične kožne lise bolezni ledvic
Purple, biconvex, film-coated oval tablets, approximately 22 x 11 mm, debossed with “572 Trı” on one side.
Vijolične, bikonveksne, ovalne filmsko obložene tablete, velikosti približno 22 x 11 mm, z vtisnjeno oznako ‘572 Trı’ na eni strani.
Purple, oval film-coated tablets with dimensions of 13.0 mm x 7.3 mm debossed with ‘u75’ on one side.
Škrlatne, ovalne, filmsko obložene tablete z dimenzijami 13,0 mm x 7,3 mm in vtisnjeno oznako u75 na eni strani.
Purpose of the medicine
Namen zdravila
Purpose of the medicine
Namen zdravila:
Purpose of the medicine
Uporaba zdravila
Purpose of the medicine
Zakaj se zdravilo uporablja
purpura (TTP) (see
purpura (TTP) (glejte
Purpura haemorrhagica has not been observed in any of the safety studies performed during development of Equilis StrepE.
Hemoragične purpure niso opazili v nobeni študiji varnosti, opravljeni med razvijanjem cepiva Equilis StrepE.
purpura, alopecia, urticaria, erythema, rash macular
purpura, alopecija, urtikarija, eritem, makulozni osip
purpura, thrombotic thrombocytopenic purpura
purpura, trombotična trombocitopenična purpura
purpura, urticaria (see section 4.3), hair loss, exanthema, dark sweat
Henoch-Schönleinova purpura, urtikarija (glejte poglavje 4.3), izguba las, eksantem, temen znoj
PURSUIT was conducted at a time when the standard of care of managing acute coronary syndromes was different from that of present times in terms of thienopyridine use and the routine use of intracoronary stents.
Študija PURSUIT je bila opravljena v času, ko je bilo standardno zdravljenje za obvladovanje akutnih koronarnih sindromov drugačno od trenutnega, kar zadeva uporabo tienopiridina antagonistov trombocitnih receptorjev ADP (P2Y12) in rutinske uporabe intrakoronarnih žilnih opornic.
PURSUIT was conducted at a time when the standard of care of managing acute coronary syndromes was different from that of present times in terms of thienopyridine use and the routine use of intracoronary stents.
Študija PURSUIT je bila opravljena v času, ko je bilo standardno zdravljenje za obvladovanje akutnih koronarnih sindromov drugačno od trenutnega, kar zadeva uporabo tienopiridinaantagonistov trombocitnih receptorjev ADP (P2Y12) in rutinske uporabe intrakoronarnih žilnih opornic.
PURSUIT was conducted at a time when the standard of care of managing acute coronary syndromes was different from that of present times in terms of thienopyridine use and the routine use of intracoronary stents.
Študija PURSUIT je bila opravljena v času, ko je bilo standardno zdravljenje za obvladovanje akutnih koronarnih sindromov drugačno od trenutnega, kar zadeva uporabo tienopiridinain rutinske uporabe intrakoronarnih žilnih opornic.
PURSUIT: This was a randomised, double-blind evaluation of the efficacy and safety of Integrilin versus placebo for reducing mortality and myocardial (re)infarction in patients with unstable angina or non-Q-wave myocardial infarction.
PURSUIT: To je bilo randomizirano, dvojno slepo ocenjevanje učinkovitosti in varnosti zdravila Integrilin v primerjavi s placebom za zmanjšanje umrljivosti in (ponovnega) miokardnega infarkta pri bolnikih z nestabilno angino pektoris ali miokardnim infarktom brez zobca Q v EKG.
pus filled bumps at application site abnormal electrocardiogram (ECG or EKG, test of heart) change in ECG or EKG high chloride levels in blood
gnojne bule na mestu uporabe, nenormalen elektrokardiogram (EKG, preiskava srca), sprememba EKG, visoke ravni kloridov v krvi.
pus filled bumps at application site abnormal electrocardiogram (ECG or EKG,test of heart) change in ECG or EKG high chloride levels in blood
gnojne bule na mestu uporabe, nenormalen elektrokardiogram (EKG, preiskava srca), sprememba EKG, visoke ravni kloridov v krvi.
PUSH & HOLD
PRITISNITE IN DRŽITE
Push air into vial.
Potisnite zrak v vialo.
Push and keep pushing the pre-filled pen down against the injection site.
Postavite in potiskajte napolnjen injekcijski peresnik navzdol, proti mestu injiciranja.
Push and screw the syringe securely onto Blue port.
Pritisnite in privijte brizgo na modri priključek, da bo varno spojena.
push and turn for opening. after removing the capsule, place the cap back on the bottle and tightly close the bottle right away after you take your dose.
odprite tako, da pritisnete navzdol in zavrtite ko ste kapsulo vzeli ven, namestite na plastenko pokrovček in jo takoj po jemanju odmerka tesno zaprite
push and turn for opening. after removing the caspsule, place the cap back on the bottle and tightly close the bottle right away after you take your dose.
odprite tako, da pritisnete navzdol in zavrtite ko ste kapsulo vzeli ven, namestite na plastenko pokrovček in jo takoj po jemanju odmerka tesno zaprite
Push and twist the needle clockwise onto the syringe.
Iglo potisnite na injekcijsko brizgo in zasučite v smeri urinega kazalca.
Push button scale
Merilna skala na pritisnem gumbu
Push button scale
Pritisni gumb Lestvica na gumbu
Push capped needle straight onto the pen.
Porinite iglo skupaj s pokrovčkom naravnost na peresnik.
PUSH capsule through the foil
POTISNITE kapsulo skozi folijo
PUSH DOWN
PRITISNITE NAVZDOL
Push down and pull up the plunger a few times to get rid of any large bubbles.
Bat nekajkrat potisnite navzdol in povlecite navzgor, da odstranite večje mehurčke.
Push down and pull up the plunger a few times to get rid of any large bubbles.
Bat nekajkrat potisnite navzdol in spet povlecite navzgor, s čimer odstranite večje mehurčke.
Push down and turn clockwise (turn a quarter of a turn to the right).
Zaporko potisnite navzdol in obrnite v smeri urinega kazalca (obrnite za četrt obrata v desno).
Push down and turn clockwise (turn to the right).
Zaporko potisnite navzdol in obrnite v smeri urinega kazalca (obrnite v desno).
Push down and turn the child resistant cap to open bottle.
Steklenico odprete tako, da zaporko, varno za otroke, potisnete navzdol in jo zavrtite.
PUSH DOWN FIRMLY
ČVRSTO POTISNITE NAVZDOL
Push DOWN on skin to unlock the Pen.
Injekcijski peresnik pritisnite NAVZDOL na kožo, da ga aktivirate.
Push down on the cap and turn counterclockwise (turn a quarter of a turn to the left).
Zaporko potiskajte navzdol in jo obračajte v nasprotni smeri urinega kazalca (obrnite za četrtino obrata v levo).